<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="134435">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01351584</url>
  </required_header>
  <id_info>
    <org_study_id>IOM TMK</org_study_id>
    <secondary_id>Tumorregister Mammakarzinom</secondary_id>
    <nct_id>NCT01351584</nct_id>
  </id_info>
  <brief_title>Tumour Registry Breast Cancer</brief_title>
  <acronym>TMK</acronym>
  <official_title>Clinical Registry to Present Treatment and Sequences of Treatments in Routine Practice in Germany</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arbeitskreis Klinische Studien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft fur Internistische Onkologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The registry aims to collect and analyse information on the antineoplastic treatment of
      breast cancer in daily routine practice of office-based and clinic-based medical oncologists
      in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TMK is a prospective, longitudinal, nation wide cohort study with the purpose to record
      information on the antineoplastic treatment of breast cancer in Germany. The registry will
      follow patients for up to five years. It will identify common therapeutic sequences and
      changes in the treatment of the disease. At inclusion, data in patient characteristics,
      comorbidities, tumor characteristics, biomarker testing and previous treatments are
      collected. During the course of observation data on all systemic treatments, radiotherapies,
      surgeries, and outcome are documented.

      The impact of nutrition (MaNut) and physical activity (MaNut) on the course of the adjuvant
      disease will be examined, as well as long-term effects of adjuvant treatment (MaTox) and the
      multiple patient-reported outcomes (MaLife).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Course of Antineoplastic Treatment</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Breast cancer patients undergoing antineoplastic or antihormonal therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer

          -  18 years and older

          -  Antineoplastic or antihormonal treatment

        Exclusion Criteria:

          -  No breast cancer

          -  Below 18 years

          -  No antineoplastic or antihormonal treatment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Tesch, MD</last_name>
    <role>Study Chair</role>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>May 9, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Advanced Breast Cancer</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>Registry</keyword>
  <keyword>Health Services Research</keyword>
  <keyword>Germany</keyword>
  <keyword>Palliative Treatment</keyword>
  <keyword>Adjuvant Drug Therapy</keyword>
  <keyword>Nutrition Assessment</keyword>
  <keyword>Physical Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
